Mono Pharmacare Past Earnings Performance
Past criteria checks 5/6
Mono Pharmacare has been growing earnings at an average annual rate of 64.8%, while the Healthcare industry saw earnings growing at 32.2% annually. Revenues have been growing at an average rate of 117% per year. Mono Pharmacare's return on equity is 8.1%, and it has net margins of 2.9%.
Key information
64.8%
Earnings growth rate
57.7%
EPS growth rate
| Healthcare Industry Growth | 29.4% |
| Revenue growth rate | 117.0% |
| Return on equity | 8.1% |
| Net Margin | 2.9% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Mono Pharmacare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 762 | 22 | 26 | 0 |
| 30 Jun 23 | 547 | 16 | 18 | 0 |
| 31 Mar 23 | 331 | 9 | 10 | 0 |
| 31 Mar 22 | 371 | 4 | 7 | 0 |
| 31 Mar 21 | 284 | 1 | 7 | 0 |
| 31 Mar 20 | 117 | 0 | 10 | 0 |
Quality Earnings: MONOPHARMA has high quality earnings.
Growing Profit Margin: MONOPHARMA's current net profit margins (2.9%) are higher than last year (1.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MONOPHARMA's earnings have grown significantly by 64.8% per year over the past 5 years.
Accelerating Growth: MONOPHARMA's earnings growth over the past year (241.6%) exceeds its 5-year average (64.8% per year).
Earnings vs Industry: MONOPHARMA earnings growth over the past year (241.6%) exceeded the Healthcare industry 27.2%.
Return on Equity
High ROE: MONOPHARMA's Return on Equity (8.1%) is considered low.